

1 First detection of Monkeypox virus genome in sewersheds in France.

2

3 Sebastien Wurtzer^{*1}, Morgane Levert², Eloise Dhenain¹, Mickael Boni³, Jean Nicolas Tournier³,
4 Nicolas Londinsky⁵, Agnès Lefranc⁶, Obepine SIG², Olivier Ferraris³, Laurent Moulin¹

5 1. Eau de Paris, Département Recherche, 33 avenue Jean Jaures, FR-94200 Ivry sur Seine,
6 France

7 2. Sorbonne Université, Groupement d'intérêt scientifique Obepine, Paris, France

8 3. Institut de recherche biomédicale des armées, 1 place Valérie-André, F-91220 Brétigny-sur-
9 Orge, France.

10 4. Ville de Paris, Direction de la propreté et de l'eau, Service technique de l'eau et de
11 l'assainissement, 27 rue du Commandeur, FR75014 Paris, France

12 5. Ville de Paris, Direction de la santé publique, Service de la santé environnementale, 11 rue
13 George Eastman, FR-75013 Paris, France.

14

15 * Correspondence: Sebastien Wurtzer, Eau de Paris, Research & Development department, 33
16 avenue Jean Jaurès. FR-94200 Ivry-sur-Seine, France. Email: sebastien.wurtzer@eaudeparis.fr

17 Keywords: Monkeypox, sewershed, sewage, wastewater, wastewater-based epidemiology

18

19 Abstract

20 A monkeypox virus outbreak is currently spreading in multiple non-endemic countries since May
21 2022. The atypical clinical profile of patients has led to a very likely underestimation of the number of
22 cases at the beginning of epidemic. The detection and quantification of the Monkeypox virus genome
23 in sewersheds in Paris (France) correlated temporally with the identification of the first case of
24 infection and the spread of the disease within the population connected to the sewage system.

25

26 Main text

27 Since May 2022, a new zoonotic infectious disease, Monkeypox, has gained attention of health
28 authorities after starting to circulate in wealthy countries usually spared. Monkeypox is caused by
29 Monkeypox virus (MPXV), a member of the *Orthopoxvirus* genus of the *Poxviridae* family, and results
30 in pox-like skin lesions, making the diagnosis difficult with smallpox and chickenpox virus infection.
31 This infection is becoming endemic in a dozen countries in West and Central Africa ¹. Human

infections with the clade 1 (former Congo Basin clade) appeared to cause more severe disease compared to the clade 2 and 3¹⁻³. Genomic sequencing of MPXV implicated in the 2022 outbreak have determined its relationship to the clade 3 (former West African clade)³⁻⁵. This Monkeypox outbreak was reported on May 7th, 2022 in the United Kingdom⁶. Since May 13th, 2022, Monkeypox cases have been reported to WHO in 12 member states for which Monkeypox was not endemic⁷. Epidemiological investigations are underway to understand the routes of transmission.

It is likely that this number of cases is greatly underestimated in countries where circulation is endemic⁸ and, as surveillance is intensified in non-endemic areas, new cases may be identified. In France, Monkeypox disease are subject to ongoing surveillance through mandatory reporting. On July 12th, 2022, 912 cases of Monkeypox were officially reported in France, 569 of which were in the Greater Paris region⁹.

MPXV infection starts with very general symptoms followed by vesicular eruptions appear about 2 days after the onset of the infection but the incubation period of the disease can be from 5 to 21 days, making the identification of contamination complex¹⁰. Little information has been reported on the virus excretion kinetics during the infection in various biological fluids that have to be analyzed. However it has been established that virus genome could be detected in skin lesions, feces, saliva, urine and semen for prolonged period (16 days since symptom onset)¹¹.

In the current context, the key objectives of surveillance and case investigation are to identify isolated cases, potential clusters and the infection origin as soon as possible in order to provide clinical care and isolate cases to prevent transmission. Containment of the virus circulation is therefore mainly based on early infection diagnosis, isolation of patient, and vaccination of the population at risk. However, this approach requires medical consultation and adherence to isolation measures of patients. The biological diagnosis carried out on people who underwent other sexually transmitted infections showed the possibility of asymptomatic carriers or patients presenting an atypical clinical presentation¹², capable of transmitting the virus, thus suggesting an underestimation of the viral circulation through the symptomatic case surveillance^{8,13,14}.

Since 2020, interest in wastewater-based epidemiology (WBE) has considerably increased with the detection and quantification of the SARS-CoV-2 genome in raw wastewater¹⁵. This approach is made possible because SARS-CoV-2 is shed in the stool of infected persons¹⁶, even if they are pre-, pauci- or asymptomatic. Numerous studies have demonstrated the correlation between the incidence of the disease, the positivity rate of tests and the concentration of viral genomes in wastewater¹⁷⁻¹⁹.

The objectives of this work were to demonstrate the presence of MPXV genome in the sewersheds in the city of Paris (France), and to date the virus emergence. Monkeypox WBE could be a

65 supplementary tool for the health authorities to better understand the viral circulation within the
66 population.

67 For more than 2 years, 16 sewersheds located in the city of Paris have been weekly sampled during
68 for 24h. First detection of MPXV genome occurred in wastewater on May 23rd, 2022 in 3 different
69 sewersheds in Paris (figure 1). The first French human case was officially reported by May 19th, 2022
70 in Paris and 3 human cases were reported on May 23rd, 2022. Based on compliance with isolation
71 measures of the first Monkeypox-diagnosed patients, genome detection of in sewersheds covering
72 other areas through the following weeks could suggest that other cases might have existed and not
73 been diagnosed yet when first human cases were identified. Out of the 16 sewersheds under
74 investigation, the fraction of positive ones for MPXV genome increased from 3/16 (May 23rd) to 9/16
75 on July 11th, 2022 indicating the virus spread in the population connected to the sewage network
76 (figure 2A). The results were in accordance with the continuous increase in new human cases
77 officially reported each week ²⁰.

78 Estimated MPXV genome concentrations were globally between 1,000 and 10,000 copies/L for less
79 than 1,000 reported infected patients (figure 2B). Excepted the first positive samples, average MPXV
80 genome concentration increased concomitantly with the number of new weekly human cases. Viral
81 genomes found in raw wastewater may originate mainly from viruses excreted in body fluids but also
82 from viruses contained in skin lesions released during hand and body washing ¹¹. With all the usual
83 precautions regarding the comparison of Ct values, the genome quantities detected in the biological
84 samples likely to contaminate the wastewater were of the same order of magnitude in COVID-19 and
85 Monkeypox patients ^{11,21,22}. Comparisons of SARS-CoV-2 and MPXV concentrations in wastewater
86 were difficult to understand because of the high underestimation of COVID-19 cases at the beginning
87 of the pandemic. In addition, contrary to biological fluids, viral genomes in scabs may be more
88 protected from degradation but may also be responsible for a less homogeneous viral concentration
89 in wastewater samples leading to a « nugget » effect such the one observed in sewersheds sampled
90 by May 23rd, 2022.

91 MPXV strains from the two worldwide outbreaks (2017-2022) belonged to MPXV clade 3 ²³. The low
92 severity during the 2022 MPXV outbreak and asymptomatic carriers may have led to erroneous
93 clinical diagnoses. Then, a silent circulation of the MPXV in naïve populations no longer immune to
94 smallpox was possible. To address this question, we conducted a retrospective analysis of randomly
95 selected samples (n=39) from August 2021, September 2021 and March 2022. MPXV viral genome
96 was not detected in any of them suggesting a date of the emerging event in May 2022. We could not
97 exclude the possibility of genetic material loss resulting from freezing/thawing of extracted nucleic

98 acids in the case of retrospective analyses. However recent phylogenetic analysis showed that MPXV
99 genomes from the 2022 outbreak came from a new lineage called B.1²⁴, confirming this hypothesis.


100 This lack of MPXV genome detection before the identification of the first human cases would also
101 strongly suggest the human origin of the viral genomes detected in the Parisian sewersheds and the
102 absence of a pre-existing animal reservoir for MPXV. However, the risk of contamination of peri-
103 domestic fauna living in sewersheds have to be investigated in correlation with the study of
104 persistence of MPXV in wastewater^{25,26}.

105 To our knowledge, this is the first study reporting the detection and quantification of MPXV genomes
106 in sewersheds. This approach has allowed to date the emergence concomitantly with the first human
107 case identified and to observe the spread of the 2022 Monkeypox epidemic in Paris (France) by
108 wastewater monitoring (n=264 samples) over a 10-month retrospective period, highlighting once
109 again the importance of WBE to establish an early warning system for epidemic emergence. The
110 interest of retrospective analyses to understand the emergence of epidemics pointed out the
111 fundamental need for wastewater sample banks. For the time being, the concentration of genomes
112 in wastewater appeared to be relatively low. Routine monitoring will be helpful to establish the viral
113 spread in the population as well as shedding kinetics in patients. Considering the mode of
114 transmission and the relatively low number of human cases, such results might be more difficult to
115 implement than for SARS-CoV-2.

116

117


118 Figure 1. Heatmap of the MPXV genome concentration in wastewater collected weekly in 16
119 sewersheds in the city of Paris, France. Grey for non-detected genome and X when the sample was
120 not available.



121


122 Figure 2. A: Frequency of positivity in sewershed samples in Paris from April 11th to July 11th, 2022.

123 New weekly human cases have been reported in open circles.



124

B: Quantification of the MPXV genome concentration in sewer sampled in Paris from April 11th to July 11th, 2022. Viral concentration of positive samples in grey dot point, average viral concentration in purple dot point and new weekly human cases in open circles.



Material & methods

Sample collection

Sixteen sewers in the city of Paris (France) were weekly sampled since May 2020 for initially SARS-CoV-2 monitoring. Twenty-four-hours composite samples (according to NF T 90-90-523-2) were taken by automated samplers. Sampling was proportional to the flow rate, it started at 7:00 AM and finished at J+1, 7:00 AM. A minimum of 144 sub-samples per day were taken during dry weather periods. Samples were taken by suction and collected in a refrigerated polyethylene tank at 5°C (+or- 3°C). The final collected volume was between 8.7 and 14L. Then samples were carefully homogenized, distributed in a 100mL polyethylene bottle, transported to the laboratory at 4°C and processed in less than 24 hours after sampling. A total of 264 samples from sewage network of the city of Paris were processed for MPXV genome detection.

Concentration method


All samples were processed as previously described¹⁸. Briefly, samples were homogenized, then 11 ml were centrifuged at 200,000 x g for 1 hour at 4°C using a XPN80 Coulter Beckman ultracentrifuge using a swing rotor (SW41Ti). Pellets were resuspended in 200 µL of Dulbecco's Phosphate-buffered saline (DPBS) 1x (reference 14190144, ThermoFisher Scientific) and pretreated for dissociating viruses and organic matter that was then removed from supernatant for improving RNA extraction efficiency, according to the manufacturer's recommendations. Supernatant was then lysed, and total nucleic acids were purified using PowerFecal Pro kit (QIAGEN) on a QIASymphony automated extractor (QIAGEN) and eluted in 50 µL of elution buffer according to manufacturer's protocol. Even if recovery rate for MPXV could not be evaluated experimentally, this protocol performed well on different types of enveloped and naked viruses²⁷. All nucleic acids were finally purified using OneStep PCR inhibitor removal kit (Zymoresearch) according the manufacturer's instructions and then directly used or stored at -80°C before use. The recovery rate of methods was estimated using bovine coronavirus spiked (mean recovery rate of 75%, ranging between 65% and 90%, Coefficient of Variation (CV%) of 12%) and the repeatability of the measurement was also evaluated on endogenous Pepper Mild Mottle Virus genome (CV% of 15%).

Detection and Molecular quantification

The genome of the MPXV was detected by qPCR using the MPXV TaqMan assay (#Vi07922155_s1, ThermoFisher scientific) targeting the gene J1L. Amplification was done using Fast virus 1-step MasterMix (ThermoFisher scientific) according to the manufacturer's instructions on ViiA7 real time thermocycler (ThermoFisher scientific). Briefly, cycling was performed as follow: polymerase activation step at 95°C for 20 sec, then amplification was done by 45 cycles of incubation at 95°C for 5 sec and 58°C for 40 sec. No template controls were included in each experiment to ensure no contamination and to set up the positivity threshold.

Some positive samples have also been amplified by digital PCR using the same MPXV TaqMan assay and QIAcuity Probe PCR Kit (QIAGEN) according to the manufacturer's recommendations. Briefly, cycling was performed as follow: polymerase activation step at 95°C for 2 min, then amplification was done by 45 cycles of incubation at 95°C for 5 sec and 58°C for 40 sec.

Concentrations obtained by dPCR and Ct resulting from qPCR assay have been plotted to establish a standard curve allowing the quantification of all samples positive in qPCR and to determine PCR efficacy.



Graphical representation

All graphics were done using GraphPad Prism software v9.0.1.

Author's contribution

SW, LM, OF, MB, AL set up analytical protocols

ED, ML, SW realized the analyses

SW, ML, LM, MB interpreted the results

SW wrote the first draft

ML, ED, LM, MB, OF, JNT, AL edited the manuscript

Obepine SIG reviewed the submitted manuscript

Funding

The analyses were carried out thanks to a financial contribution from the City of Paris, Eau de Paris and Obepine (French Research ministry).

Conflicts of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Data availability statement

All data produced in the present study are available upon reasonable request to the authors.

Acknowledgments

OBEFINE scientific interest group is composed by Boni M. (Institut de recherche biomédicale des armées), Wurtzer S., Moulin L. (Eau de Paris), Mouchel JM., Maday Y., Marechal V. (Sorbonne universite), Le Guyader S. (IFREMER), Bertrand I., Gantzer C. (Universite de Lorraine)

References

- (1) Beer, E. M.; Rao, V. B. A Systematic Review of the Epidemiology of Human Monkeypox Outbreaks and Implications for Outbreak Strategy. *PLoS Negl Trop Dis* **2019**, *13* (10), e0007791. <https://doi.org/10.1371/journal.pntd.0007791>.
- (2) Yinka-Ogunleye, A.; Aruna, O.; Dalhat, M.; Ogoina, D.; McCollum, A.; Disu, Y.; Mamadu, I.; Akinpelu, A.; Ahmad, A.; Burga, J.; Ndoreraho, A.; Nkuzimana, E.; Manneh, L.; Mohammed, A.; Adeoye, O.; Tom-Aba, D.; Silenou, B.; Ipadeola, O.; Saleh, M.; Adeyemo, A.; Nwadiutor, I.; Aworabhi, N.; Uke, P.; John, D.; Wakama, P.; Reynolds, M.; Mauldin, M. R.; Doty, J.; Wilkins, K.; Musa, J.; Khalakdina, A.; Adedeji, A.; Mba, N.; Ojo, O.; Krause, G.; Ihekweazu, C.; CDC Monkeypox Outbreak Team. Outbreak of Human Monkeypox in Nigeria in 2017-18: A Clinical and Epidemiological Report. *Lancet Infect Dis* **2019**, *19* (8), 872–879. [https://doi.org/10.1016/S1473-3099\(19\)30294-4](https://doi.org/10.1016/S1473-3099(19)30294-4).
- (3) Likos, A. M.; Sammons, S. A.; Olson, V. A.; Frace, A. M.; Li, Y.; Olsen-Rasmussen, M.; Davidson, W.; Galloway, R.; Khristova, M. L.; Reynolds, M. G.; Zhao, H.; Carroll, D. S.; Curns, A.; Formenty, P.; Esposito, J. J.; Regnery, R. L.; Damon, I. K. A Tale of Two Clades: Monkeypox Viruses. *J Gen Virol* **2005**, *86* (Pt 10), 2661–2672. <https://doi.org/10.1099/vir.0.81215-0>.

- 217 (4) Antinori, A.; Mazzotta, V.; Vita, S.; Carletti, F.; Tacconi, D.; Lapini, L. E.; D'Abramo, A.; Cicalini,
218 S.; Lapa, D.; Pittalis, S.; Puro, V.; Rivano Capparuccia, M.; Giombini, E.; Gruber, C. E. M.;
219 Garbuglia, A. R.; Marani, A.; Vairo, F.; Girardi, E.; Vaia, F.; Nicastri, E.; Agresta, A.; Baldini, F.;
220 Bartoli, T. A.; Beccacece, A.; Bellagamba, R.; Bettini, A.; Bevilacqua, N.; Camici, M.; Colavita, F.;
221 Corpolongo, A.; De Carli, G.; De Zottis, F.; Faraglia, F.; Francalancia, M.; Fusco, C. M.;
222 Gagliardini, R.; Gebremeskel, S.; Giancola, M. L.; Gramigna, G.; Grilli, E.; Grisetti, S.; Lanini, S.;
223 Maffongelli, G.; Mariano, A.; Mastroiosa, I.; Matusali, G.; Meschi, S.; Minosse, C.; Moccione,
224 M.; Mondì, A.; Mondillo, V.; Orchi, N.; Ottou, S.; Pinnetti, C.; Rosati, S.; Rueca, M.; Scorzolini,
225 L.; Specchiarello, E.; Vergori, A. Epidemiological, Clinical and Virological Characteristics of Four
226 Cases of Monkeypox Support Transmission through Sexual Contact, Italy, May 2022. *Euro*
227 *Surveill* **2022**, 27 (22), 2200421. <https://doi.org/10.2807/1560-7917.ES.2022.27.22.2200421>.
228 (5) Frenois-Veyrat, G.; Gallardo, F.; Gorgé, O.; Marcheteau, E.; Ferraris, O.; Baidaliuk, A.; Favier,
229 A.-L.; Enfroy, C.; Holy, X.; Lourenco, J.; Khoury, R.; Nolent, F.; Groenbach, D. W.; Hruby, D.;
230 Ferrier, A.; Iseni, F.; Simon-Lorière, E.; Tournier, J.-N. *Tecovirimat Is Highly Efficient on the*
231 *Monkeypox Virus Lineage Responsible for the International 2022 Outbreak*; preprint;
232 Microbiology, 2022. <https://doi.org/10.1101/2022.07.19.500484>.
233 (6) UK Health Security Agency. *Monkeypox cases confirmed in England*.
234 [https://www.gov.uk/government/news/monkeypox-cases-confirmed-in-england-latest-](https://www.gov.uk/government/news/monkeypox-cases-confirmed-in-england-latest-updates)
235 [updates](https://www.gov.uk/government/news/monkeypox-cases-confirmed-in-england-latest-updates).
236 (7) European Centre for Disease Prevention and Control. *Risk assessment: Monkeypox multi-*
237 *country outbreak*. [https://www.ecdc.europa.eu/en/publications-data/risk-assessment-](https://www.ecdc.europa.eu/en/publications-data/risk-assessment-monkeypox-multi-country-outbreak)
238 [monkeypox-multi-country-outbreak](https://www.ecdc.europa.eu/en/publications-data/risk-assessment-monkeypox-multi-country-outbreak).
239 (8) World Health Organization. *Multi-country monkeypox outbreak in non-endemic countries*.
240 <https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON385>.
241 (9) Santé publique France. *Surveillance nationale des cas de syndrome inflammatoire multi-*
242 *systémique pédiatrique (PIMS)*. [https://www.santepubliquefrance.fr/etudes-et-](https://www.santepubliquefrance.fr/etudes-et-enquetes/surveillance-nationale-des-cas-de-syndrome-inflammatoire-multi-systemique-pediatrique-pims)
243 [enquetes/surveillance-nationale-des-cas-de-syndrome-inflammatoire-multi-systemique-](https://www.santepubliquefrance.fr/etudes-et-enquetes/surveillance-nationale-des-cas-de-syndrome-inflammatoire-multi-systemique-pediatrique-pims)
244 [pediatrique-pims](https://www.santepubliquefrance.fr/etudes-et-enquetes/surveillance-nationale-des-cas-de-syndrome-inflammatoire-multi-systemique-pediatrique-pims).
245 (10) World Health Organization. *Monkeypox*. [https://www.who.int/en/news-room/fact-](https://www.who.int/en/news-room/fact-sheets/detail/monkeypox)
246 [sheets/detail/monkeypox](https://www.who.int/en/news-room/fact-sheets/detail/monkeypox).
247 (11) Peiró-Mestres, A.; Fuertes, I.; Camprubí-Ferrer, D.; Marcos, M. Á.; Vilella, A.; Navarro, M.;
248 Rodríguez-Elena, L.; Riera, J.; Català, A.; Martínez, M. J.; Blanco, J. L.; Group, on behalf of the
249 H. C. de B. M. S. Frequent Detection of Monkeypox Virus DNA in Saliva, Semen, and Other
250 Clinical Samples from 12 Patients, Barcelona, Spain, May to June 2022. *Eurosurveillance* **2022**,
251 27 (28), 2200503. <https://doi.org/10.2807/1560-7917.ES.2022.27.28.2200503>.
252 (12) De Baetselier, I.; Van Dijck, C.; Kenyon, C.; Coppens, J.; Van den Bossche, D.; Smet, H.;
253 Liesenborghs, L.; Vanroye, F.; de Block, T.; Rezende, A.; Florence, E.; Vercauteren, K.; Van
254 Esbroeck, M.; the Monkeypox study group. *Asymptomatic Monkeypox Virus Infections among*
255 *Male Sexual Health Clinic Attendees in Belgium*; preprint; Infectious Diseases (except
256 HIV/AIDS), 2022. <https://doi.org/10.1101/2022.07.04.22277226>.
257 (13) Cohen, Jon. *Monkeypox is a new global threat. African scientists know what the world is up*
258 *against*. [https://www.science.org/content/article/monkeypox-is-a-new-global-threat-african-](https://www.science.org/content/article/monkeypox-is-a-new-global-threat-african-scientists-know-what-the-world-is-up-against)
259 [scientists-know-what-the-world-is-up-against](https://www.science.org/content/article/monkeypox-is-a-new-global-threat-african-scientists-know-what-the-world-is-up-against) (accessed 2022-07-19).
260 (14) Cluzel, N.; Courbariaux, M.; Wang, S.; Moulin, L.; Wurtzer, S.; Bertrand, I.; Laurent, K.;
261 Monfort, P.; Gantzer, C.; Guyader, S. L.; Boni, M.; Mouchel, J.-M.; Maréchal, V.; Nuel, G.;
262 Madaï, Y. A Nationwide Indicator to Smooth and Normalize Heterogeneous SARS-CoV-2 RNA
263 Data in Wastewater. *Environ Int* **2022**, 158, 106998.
264 <https://doi.org/10.1016/j.envint.2021.106998>.
265 (15) Lesté-Lasserre, C. Coronavirus Found in Paris Sewage Points to Early Warning System. *Science*
266 **2020**. <https://doi.org/10.1126/science.abc3799>.
267 (16) Parasa, S.; Desai, M.; Thoguluva Chandrasekar, V.; Patel, H. K.; Kennedy, K. F.; Roesch, T.;
268 Spadaccini, M.; Colombo, M.; Gabbiadini, R.; Artifon, E. L. A.; Repici, A.; Sharma, P. Prevalence

- of Gastrointestinal Symptoms and Fecal Viral Shedding in Patients With Coronavirus Disease
2019: A Systematic Review and Meta-Analysis. *JAMA Netw Open* **2020**, 3 (6), e2011335.
<https://doi.org/10.1001/jamanetworkopen.2020.11335>.
- (17) Medema, G.; Heijnen, L.; Elsinga, G.; Italiaander, R.; Brouwer, A. Presence of SARS-
Coronavirus-2 RNA in Sewage and Correlation with Reported COVID-19 Prevalence in the Early
Stage of the Epidemic in The Netherlands. *Environmental Science* **2020**, No. 7, 511–516.
- (18) Wurtzer, S.; Marechal, V.; Mouchel, J.-M.; Maday, Y.; Teyssou, R.; Richard, E.; Almayrac, J.-L.;
Moulin, L. Evaluation of Lockdown Effect on SARS-CoV-2 Dynamics through Viral Genome
Quantification in Waste Water, Greater Paris, France, 5 March to 23 April 2020.
Eurosurveillance **2020**, 25 (50), 2000776. <https://doi.org/10.2807/1560-7917.ES.2020.25.50.2000776>.
- (19) Randazzo, W.; Cuevas-Ferrando, E.; Sanjuan, R.; Domingo-Calap, P.; Sanchez, G. Metropolitan
Wastewater Analysis for COVID-19 Epidemiological Surveillance. *International Journal of
Hygiene and Environmental Health* **2020**, 230. <https://doi.org/10.1016/j.ijheh.2020.113621>.
- (20) Santé publique France. *Cas de variole du singe*. <https://www.santepubliquefrance.fr/les-actualites/2022/cas-de-variole-du-singe-point-de-situation-au-12-juillet-2022>.
- (21) Wang, W.; Xu, Y.; Gao, R.; Lu, R.; Han, K.; Wu, G.; Tan, W. Detection of SARS-CoV-2 in Different
Types of Clinical Specimens. *JAMA* **2020**. <https://doi.org/10.1001/jama.2020.3786>.
- (22) Perrella, A.; Brita, M.; Coletta, F.; Cotena, S.; De Marco, G.; Longobardi, A.; Sala, C.; Sannino,
D.; Tomasello, A.; Perrella, M.; Russo, G.; Tarsitano, M.; Chetta, M.; Della Monica, M.; Orlando,
V.; Coscioni, E.; Villani, R. SARS-CoV-2 in Urine May Predict a Severe Evolution of COVID-19. *J
Clin Med* **2021**, 10 (18), 4061. <https://doi.org/10.3390/jcm10184061>.
- (23) World Health Organization. *Monkeypox - United Kingdom of Great Britain and Northern
Ireland ex Nigeria*. [https://www.who.int/emergencies/disease-outbreak-
news/item/monkeypox---united-kingdom-of-great-britain-and-northern-ireland-ex-nigeria](https://www.who.int/emergencies/disease-outbreak-news/item/monkeypox---united-kingdom-of-great-britain-and-northern-ireland-ex-nigeria)
(accessed 2022-07-22).
- (24) Luna, N.; Ramírez, A. L.; Muñoz, M.; Ballesteros, N.; Patiño, L. H.; Castañeda, S. A.; Bonilla-
Aldana, D. K.; Paniz-Mondolfi, A.; Ramírez, J. D. Phylogenomic Analysis of the Monkeypox
Virus (MPXV) 2022 Outbreak: Emergence of a Novel Viral Lineage? *Travel Medicine and
Infectious Disease* **2022**, 49, 102402. <https://doi.org/10.1016/j.tmaid.2022.102402>.
- (25) Song, T.-Z.; Zheng, Y.-T. Monkeypox, Wild Animals, and Potential Big Problem. *Zoological
Research* **2022**, 43 (4), 612–614. <https://doi.org/10.24272/j.issn.2095-8137.2022.217>.
- (26) Bonilla-Aldana, D. K.; Rodriguez-Morales, A. J. Is Monkeypox Another Reemerging Viral
Zoonosis with Many Animal Hosts yet to Be Defined? *Veterinary Quarterly* **2022**, 42 (1), 148–
150. <https://doi.org/10.1080/01652176.2022.2088881>.
- (27) Wurtzer, S.; Waldman, P.; Levert, M.; Cluzel, N.; Almayrac, J. L.; Charpentier, C.; Masnada, S.;
Gillon-Ritz, M.; Mouchel, J. M.; Maday, Y.; Boni, M.; Marechal, V.; Moulin, L. SARS-CoV-2
Genome Quantification in Wastewaters at Regional and City Scale Allows Precise Monitoring
of the Whole Outbreaks Dynamics and Variants Spreading in the Population. *Science of The
Total Environment* **2022**, 810, 152213. <https://doi.org/10.1016/j.scitotenv.2021.152213>.